Efficacy and safety of cadonilimab in the treatment of malignant solid tumors：a meta-analysis
- VernacularTitle:卡度尼利单抗治疗恶性实体肿瘤有效性和安全性的Meta分析
- Author:
Peiwen HUANG
1
;
Yueyue LI
1
;
Long WANG
2
;
Xudong WANG
1
Author Information
1. Dept. of Pharmacy，the Third Affiliated Hospital of Anhui Medical University/Hefei First People’s Hospital，Hefei 230071，China
2. Dept. of Pharmacy，the Third People’s Hospital of Bengbu，Anhui Bengbu 233099，China
- Publication Type:Journal Article
- Keywords:
cadonilimab;
programmed cell death-1
- From:
China Pharmacy
2025;36(24):3125-3131
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To systematically evaluate the efficacy and safety of cadonilimab in patients with malignant solid tumors. METHODS The related literature was comprehensively searched from PubMed， Embase， Cochrane Library， Web of Science， CNKI， Wanfang， VIP， and CBM databases， and the search time ranged from the establishment date to August 2025. Literature screening was strictly adhered to predefined inclusion and exclusion criteria， the quality of randomized controlled trials and single-arm studies were evaluated using the Cochrane risk of bias assessment tool and the MINORS scale， respectively. Meta- analysis was conducted using RevMan and Stata software. RESULTS A total of 23 studies （2 randomized controlled trials， 21 single-arm studies） with 2 539 patients were included. Pooled analysis of RCTs showed that the objective response rate （ORR） was significantly higher in the trial group than in the control group （RR＝1.24， 95%CI：1.08-1.42； P＝0.002）， but the risk of any-grade immune-related adverse events （irAEs） was also significantly increased （RR＝5.36， 95%CI：3.88-7.42； P＜0.000 01）. Pooled analysis of single-arm studies showed that the ORR of cadonilimab was 39.8% （95%CI：31.0%-49.7%）， and the median progression free survival was 6.39 months （95%CI：4.11-8.67）. Subgroup analysis indicated that the ORR for patients with cervical cancer and gastric or gastroesophageal junction adenocarcinoma were 54.5% （95%CI：40.8%-67.6%） and 54.1% （95%CI： 45.1%-62.7%）， respectively. In terms of safety， the incidences of grade ≥3 treatment-related adverse events and irAEs were 41.0% （95%CI： 31.0%-51.0%） and 9.9% （95%CI： 7.4%-13.8%）， respectively. CONCLUSIONS Cadonilimab demonstrates significant efficacy advantages in multiple solid tumors， with manageable safety， holding particularly important clinical value in cervical cancer and gastric or gastroesophageal junction adenocarcinoma.
